下咽癌治疗的研究进展
Research Progress on the Treatment of Hypopharyngeal Cancer
DOI: 10.12677/ACM.2023.134782, PDF,   
作者: 童运乾, 赵化荣*:新疆医科大学第一附属医院肿瘤中心,新疆 乌鲁木齐
关键词: 下咽癌手术器官保留Hypopharyngeal Cancer Surgery Organ Preservation
摘要: 下咽癌在解剖学上下咽包括侧咽、后咽壁、梨状窝和通向食管入口的环状后区。在临床实践中,下咽癌经常出现在晚期,严重影响了患者的生活质量。尽管头颈部癌症的整体肿瘤学治疗取得了进展,但下咽癌的预后仍相对较差,多年来生存率仅略有改善。下咽癌近50%的患者在诊断后的第一年内复发,且多为远处转移。下咽癌的可用治疗方案包括手术、放疗或化疗,具体取决于临床阶段和共病情况。下咽癌症的治疗仍然是一个挑战,需要多学科的方法来制定最佳治疗方案。总体目标是优化存活率,并在从肿瘤学角度看可行时提供功能性器官保存。本文围绕下咽癌治疗,基于证据的治疗方案进行全面综述,特别关注器官保留模式的演变。
Abstract: Hypopharyngeal cancer anatomically includes the lateral pharynx, the posterior pharyngeal wall, the pyriform fossa and the posterior cricoid region leading to the entrance of the esophagus. In clin-ical practice, hypopharyngeal cancer is frequently seen in advanced stages, which severely affects the quality of life of patients. Despite advances in the overall oncologic treatment of head and neck cancers, the prognosis for hypopharyngeal cancer remains relatively poor, with only modest im-provements in survival over the years. Nearly 50% of patients with hypopharyngeal cancer recur within the first year of diagnosis, and most have distant metastases. Available treatment options for hypopharyngeal cancer include surgery, radiation therapy or chemotherapy, depending on the clinical stage and co-morbidities. The treatment of hypopharyngeal cancer remains a challenge and requires a multidisciplinary approach to develop optimal treatment options. The overall goal is to optimize survival and provide functional organ preservation when feasible from an oncologic per-spective. This article provides a comprehensive review of evidence-based treatment options around hypopharyngeal cancer treatment, with a particular focus on the evolution of organ preservation paradigms.
文章引用:童运乾, 赵化荣. 下咽癌治疗的研究进展[J]. 临床医学进展, 2023, 13(4): 5527-5535. https://doi.org/10.12677/ACM.2023.134782

参考文献

[1] Newman, J.R., Connolly, T.M., Illing, E.A., et al. (2015) Survival Trends in Hypopharyngeal Cancer: A Popula-tion-Based Review. Laryngoscope, 125, 624-629. [Google Scholar] [CrossRef] [PubMed]
[2] Hall, S.F., Groome, P.A., Irish, J., et al. (2008) The Natural History of Patients with Squamous Cell Carcinoma of the Hypopharynx. Laryngo-scope, 118, 1362-1371. [Google Scholar] [CrossRef
[3] Avinçsal, M.O., Shinomiya, H., Teshima, M., et al. (2018) Impact of Alcohol Dehydrogenase Aldehyde Dehydrogenase Polymorphism on Clinical Out-come in Patients with Hypopharyngeal Cancer. Head & Neck, 40, 770-777. [Google Scholar] [CrossRef] [PubMed]
[4] Eckel, H.E., Staar, S., Volling, P., et al. (2001) Surgical Treatment for Hy-popharynx Carcinoma: Feasibility Mortality and Results. Otolaryngology—Head and Neck Surgery, 124, 561-569. [Google Scholar] [CrossRef] [PubMed]
[5] Lee, J.K., Lee, K.H., Kim, S.A., et al. (2018) p16 as a Prognostic Factor for the Response to Induction Chemotherapy in Advanced Hypopharyngeal Squamous Cell Carcinoma. Oncology Letters, 15, 6571-6577. [Google Scholar] [CrossRef] [PubMed]
[6] Chung, E.J., Lee, S.H., Baek, S.H., et al. (2014) Pattern of Cervical Lymph Node Metastasis in Medial Wall Pyriform Sinus Carcinoma. Laryngoscope, 124, 882-887. [Google Scholar] [CrossRef] [PubMed]
[7] Kotwall, C.S.K., Razack, M.R.U., Bakamjian, V., et al. (1987) Metastatic Patterns Insquamous Cell Cancer of the Head and Neck. The American Journal of Surgery, 154, 438-442. [Google Scholar] [CrossRef] [PubMed]
[8] Jager Ea, L.H. and Caldas-Magalhaes, J. (2016) Validated Guidelines for Tumor Delineation on Magnetic Resonance Imaging for Laryngeal and Hypopharyngeal Cancer. Acta Oncologica (Madr), 55, 1305-1312. [Google Scholar] [CrossRef
[9] Fukuhara, T., Matsuda, E., Hattori, Y., et al. (2017) Use-fulness of Ultrasound for Assessing the Primary Tumor of Hypopharyngeal Carcinoma. Laryngoscope Investigative Otolaryngology, 2, 390-394. [Google Scholar] [CrossRef] [PubMed]
[10] Henriques De Figueiredo, B. and Fortpied, C. (2016) Long-Term Update of the 24954 EORTC Phase III Trial on Larynx Preservation. European Journal of Cancer, 65, 109-112. [Google Scholar] [CrossRef] [PubMed]
[11] Lefebvre, J.L., Pointreau, Y., et al. (2013) Induction Chemotherapy Followed by either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study. Journal of Clinical Oncology, 31, 853-859. [Google Scholar] [CrossRef
[12] Machtay, M., Moughan, J., et al. (2012) Hypopharyngeal Dose Is Associated with Severe Late Toxicity in Locally Advanced Head-and-Neck Cancer: An RTOG Analysis. International Journal of Radiation Oncology, Biology, Physics, 84, 983-989. [Google Scholar] [CrossRef] [PubMed]
[13] Lefebvre, J.L., Pointreau, Y., Rolland, F., et al. (2013) Induction Chemotherapy Followed by either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study. Journal of Clinical Oncology, 31, 853-859. [Google Scholar] [CrossRef
[14] Lefebvre, J.L., Rolland, F., Tesselaar, M., et al. (2009) Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy. JNCI: Journal of the National Cancer Institute, 101, 142-152. [Google Scholar] [CrossRef] [PubMed]
[15] Prades, J.M., Lallemant, B., Garrel, R., et al. (2010) Randomized Phase III Trial Comparing Induction Chemotherapy Followed by Radiotherapy to Concomitant Chemoradiotherapy for Laryngeal Preservation in T3M0 Pyriform Sinus Carcinoma. Acta Oto-Laryngologica, 130, 150-155. [Google Scholar] [CrossRef] [PubMed]
[16] Posner, M.R., Hershock, D.M., Blajman, C.R., et al. (2007) Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. The New England Journal of Medicine, 357, 1705-1715. [Google Scholar] [CrossRef
[17] Masuda, M., Wakasaki, T., Toh, S., et al. (2017) Utility of Chemora-dioselection for the Optimization of Treatment Intensity in Advanced Hypopharyngeal and Laryngeal Carcinoma. Molec-ular and Clinical Oncology, 7, 965-970. [Google Scholar] [CrossRef] [PubMed]
[18] Wuthrick, E.J., Zhang, Q., Machtay, M., et al. (2015) Institutional Clinical Trial Accrual Volume and Survival of Patients with Head and Neck Cancer. Journal of Clinical Oncology, 33, 156-164. [Google Scholar] [CrossRef
[19] Juloori, A., Koyfman, S.A., Geiger, J.L., et al. (2018) Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-Term Outcomes and Tox-icity. Anticancer Research, 38, 3543-3549. [Google Scholar] [CrossRef] [PubMed]
[20] Lefebvre, J.L. (2009) Surgery for Laryngopharyngeal SCC in the Era of Organ Preservation. Clinical and Experimental Otorhinolaryngology, 2, 159-163. [Google Scholar] [CrossRef] [PubMed]
[21] Durmus, K., Kucur, C., Uysal, I.O., et al. (2015) Feasibility and Clinical Outcomes of Transoral Robotic Surgery and Transoral Robot-Assisted Carbon Dioxide Laser for Hypopharyn-geal Carcinoma. Journal of Craniofacial Surgery, 26, 235-237. [Google Scholar] [CrossRef
[22] Lörincz, B.B., Busch, C.J., Möckelmann, N., et al. (2015) Feasibility and Safety of Transoral Robotic Surgery (TORS) for Early Hypopharyngeal Cancer: A Subset Analysis of the Hamburg University TORS-Trial. European Archives of Oto-Rhino-Laryngology, 272, 2993-2998. [Google Scholar] [CrossRef] [PubMed]
[23] Park, Y.M., Kim, W.S., Byeon, H.K., et al. (2010) Feasiblity of Transoral Robotic Hypopharyngectomy for Early-Stage Hypopharyngeal Carcinoma. Oral Oncology, 46, 597-602. [Google Scholar] [CrossRef] [PubMed]
[24] Dziegielewski, P.T., Kang, S.Y. and Ozer, E. (2015) Transoral Robotic Surgery (TORS) for Laryngeal and Hypopharyngeal Cancers. Journal of Surgical Oncology, 112, 702-706. [Google Scholar] [CrossRef] [PubMed]
[25] Hanna, E., Sherman, A., Cash, D., et al. (2004) Quality of Life for Patients Following Total Laryngectomy vs Chemoradiation for Laryngeal Preservation. Archives of Otorhinolaryngolo-gy-Head & Neck Surgery, 130, 875-879. [Google Scholar] [CrossRef] [PubMed]
[26] Singer, S., Danker, H., Guntinas-Lichius, O., et al. (2014) Quality of Life before and after Total Laryngectomy: Results of a Multicenter Prospective Cohort Study. Head & Neck, 36, 359-368. [Google Scholar] [CrossRef] [PubMed]
[27] Ferris, R.L., Blumenschein, G., Fayette, J., et al. (2016) Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. The New England Journal of Medicine, 375, 1856-1867. [Google Scholar] [CrossRef
[28] Chow, L.Q.M., Haddad, R., Gupta, S., et al. (2016) Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results from the Phase Ib KEYNOTE-012 Expansion Cohort. Journal of Clinical Oncology, 34, 3838-3845. [Google Scholar] [CrossRef
[29] Hasegawa, Y., Goto, M., Hanai, N., et al. (2018) Predictive Bi-omarkers for Combined Chemotherapy with 5-Fluo- rouracil and Cisplatin in Oro- and Hypopharyngeal Cancers. Molec-ular and Clinical Oncology, 8, 378-386. [Google Scholar] [CrossRef] [PubMed]